NPM1 and acute myeloid leukemia: In particular, we are studying the effect of HHT (Homoharringtonine, also named Omacetaxine mepesuccinate) and ABT-199 (Venetoclax) on models of acute myeloid leukemia (AML), specifically AML with NPM1 mutation, which is the most frequent AML in adult patients, accounting for about one-third of all cases [37].